Infigratinib

英非替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameInfigratinib
Drug Alias NameInfigratinibumInfigratinib phosphateTRUSELTIQFebseltiqBGJ-398 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists
TargetsFibroblast growth factor receptor 2Fibroblast growth factor receptor 3Fibroblast growth factor receptor 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursAchondroplasia +[25] 
Global Approved IndicationsCholangiocarcinoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/05/28
Country/TerritoryBelgiumBulgariaCanada +[28] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesAlcami Carolinas CorporationKyowa Kirin Co LtdQed Therapeutics Inc +[7] 
Inactive CompaniesDana-Farber Cancer InstituteUT Health San AntonioRoswell Park Cancer Institute +[8] 
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursAchondroplasia +[5] 
Inactive IndicationsUrinary Bladder NeoplasmsUterine Cervical NeoplasmsCentral Nervous System Neoplasms +[20] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG